Xtant Medical Holdings Inc【XTNT】株式ニュース

Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductApril 13, 2026 9:04 AM
PR Newswire (US)

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical device manufacturer, today announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST® Bellows for high-performance hemostasis following certain surgical procedures.

Sean Browne, President and CEO of Xtant Medical, stated, "We are excited to partner with Dilon Technologies to bring HEMOBLAST, a highly complementary hemostatic technology, to a broader group of surgeons. This agreement expands our portfolio with a unique and versatile hemostatic solution while also significantly bolstering our own commercial capabilities with the integration of Dilon's approximately 20-person U.S. sales team into our organization. With our broadened product offering and enhanced reach and sales capabilities, we believe we can better address the comprehensive needs of surgeons and patients alike while meaningfully expanding our addressable market."George Makhoul, CEO of Dilon Technologies, stated, "HEMOBLAST is highly differentiated in the surgical hemostat market with its unique composition as the only collagen/thrombin formulation that provides applicability across minimal, mild, and moderate bleeding types, and we are very pleased to entrust its future growth to Xtant. As a recognized leader in the manufacture and distribution of novel biologics solutions for a range of surgical applications, we believe Xtant is the ideal partner to extend the U.S. commercial reach of HEMOBLAST and achieve its full market potential." HEMOBLAST Bellows is a pre-loaded hemostatic powder indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in ophthalmic and urological procedures. HEMOBLAST is the only hemostat containing collagen (mechanical hemostat), human derived thrombin (which converts fibrinogen to fibrin, a basic element required for blood clotting), and bovine-derived chondroitin sulfate (which provides cohesion between the wound and surrounding tissue). Delivered via a pre-loaded bellows applicator, HEMOBLAST requires no prep prior to use. Xtant plans to update its full-year 2026 financial guidance in light of the new distribution arrangement in connection with the release of its first quarter 2026 financial results.About Dilon Technologies® Inc.Dilon Technologies Inc., a medical device manufacturer based in Newport News, Virginia, strives to improve the quality of care by providing a wide range of innovative medical device technology that benefits patients around the world. Dilon has a strong medical device portfolio which includes HEMOBLAST Bellows, the only combination powdered surgical hemostat that contains collagen, thrombin and chondroitin sulfate, MarginProbe, a groundbreaking technology for accurate margin assessment in breast cancer surgery, the Navigator System, a surgical gamma probe system for radio-guided lymphatic mapping and tumor localization, TrueView Pro 100, a specimen radiography system (SRS) that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue, and the CoPilot, an innovative, portable, and easy to use video laryngoscope.About Xtant Medical Holdings, Inc.Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include Xtant's expectations regarding the exclusive distribution arrangement and its ability to better address the comprehensive needs of surgeons and patients. Xtant cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the success of the distribution arrangement and the HEMOBLAST® Bellows product, including future U.S. sales and the additional U.S. sales personnel and their impact on Xtant's business and operating results; the possibility that the distribution agreement may be terminated by either party; the effect of the distribution agreement on Xtant's business, including its relationships with other distributors, independent sales representatives and personnel, and its business and operating results; Xtant's future operating and financial performance and its ability to increase or maintain revenue; the success of Xtant's expanded field sales force to improve Xtant's reach and leverage its outstanding contract portfolio and independent agent network; its ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed, and other risk factors contained in Xtant's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 31, 2026 and subsequent SEC filings by Xtant. Investors are encouraged to read Xtant's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Xtant undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to Xtant or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-and-dilon-technologies-announce-exclusive-us-distribution-agreement-for-dilons-hemoblast-bellows-product-302740499.htmlSOURCE Xtant Medical Holdings, Inc.

Original: Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product

Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 31, 2026 7:00 AM
PR Newswire (US)

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-yearXtant delivers positive net income, adjusted EBITDA and operating cash flowTotal cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestitureBELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.

Fourth Quarter 2025 Financial HighlightsRevenue of $32.4 million, up approximately 3% compared to the prior year quarterCompany's earlier-than-anticipated closing of the Companion Spine transaction reduced fourth quarter 2025 revenue by an estimated $2.0 millionGross margin of 54.9% compared to 50.8% for the prior year quarterNet income of $0.1 million compared to a net loss of $3.2 million in the prior year quarterNon-GAAP adjusted EBITDA of $1.9 million compared to adjusted EBITDA of $0.4 million in the prior year quarterFull-Year 2025 Financial HighlightsRevenue of $134.0 million, up approximately 14% over the full-year 2024Gross margin of 62.9%, compared to 58.2% for the full year 2024Net income of $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million, or a net loss of $0.12 per basic and diluted share, for the full year 2024Non-GAAP adjusted EBITDA of $16.3 million compared to an adjusted EBITDA loss of $2.3 million for the full year 2024Net cash provided by operations of $12.5 million compared to net cash used in operations of $11.9 million for the full year 2024Fourth Quarter 2025 and Recent Business Highlights Completed the previously announced sale of Xtant's non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine for a total sale price of $21.4 million in cash.Announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite (HA), the most commonly used synthetic material.Announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.Sean Browne, President and CEO of Xtant Medical, stated, "Our fourth quarter 2025 caps a truly transformational year for Xtant, during which we meaningfully sharpened our focus on our core biologics business while driving the new product innovation for which we are known. Along the way, in 2025 we achieved profitability and cash flow generation, reflecting robust topline growth, targeted R&D investments, and prudent expense management. We also took advantage of a short-term license and royalty opportunity through our amnio line in the advanced wound care market. Those cash flows, along with the divestiture of certain non-core products and operations, provided Xtant with the capital to focus on internally developing our advanced biologics product lines, including new products released in 2025. With this foundation in place, we began to opportunistically add to our field sales force in the fourth quarter 2025 and into the first quarter of 2026 to improve our reach and leverage our outstanding contract portfolio and independent agent network.""Looking ahead to 2026, with the recent receipt of amounts previously outstanding under our note receivable from the Companion Spine transaction, we have increased our current cash position to over $22 million while reducing our term loan balance to $11.2 million. Given our significantly strengthened financial position, we do not see any need to raise additional outside capital to run our operations and we expect to be free cash flow positive in 2026. Moreover, this year we plan to lean into our strengths in biologics and invest in our commercial team to focus on profitably growing our core biologics business. With the substantial progress made in 2025, I am excited for this year and beyond," Mr. Browne concluded.Fourth Quarter and Full-Year 2025 Financial ResultsFourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024. The increase is due primarily to higher license revenue, partly offset by one less month of Coflex and CoFix and related international hardware sales in 2025 as a result of the sale of those businesses to Companion Spine in early December. For the full year, total revenue of $134.0 million increased 14% over $117.3 million for the full year 2024.Gross margin for the fourth quarter of 2025 was 54.9%, compared to 50.8% for the same period in 2024. For the full year 2025, gross margin was 62.9%, compared to 58.2% for the full year 2024. These increases were primarily attributable to sales mix and greater scale, partially offset by increased charges for excess and obsolete inventory, in particular, a $1.3 million charge related to excess and obsolete inventory associated with the launch of the Cortera® Fixation System.Operating expenses for the fourth quarter of 2025 totaled $18.7 million, compared to $17.9 million for the fourth quarter of 2024. Full year 2025 total operating expenses were $77.0 million, compared to $80.3 million for the full year 2024. The increase in fourth quarter 2025 operating expenses was primarily due to increases in various compensation plans and the year-over-year decline was primarily driven by reduced commission expense.Net income for the fourth quarter 2025 totaled $0.1 million, compared to a net loss of $3.2 million for the fourth quarter of 2024. For the full year 2025, net income was $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million, or a new loss of $0.12 per basic and diluted share, for the full year 2024.Non-GAAP adjusted EBITDA for the fourth quarter of 2025 totaled $1.9 million, compared to adjusted EBITDA of $0.4 million for the same period in 2024. For the full year 2025, non-GAAP adjusted EBITDA was $16.3 million, compared to an adjusted EBITDA loss of $2.3 million for the full year 2024.The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related expense, acquisition-related fair value adjustments, gain on divestiture, and unrealized foreign currency translation gain or loss. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.As of December 31, 2025, the Company had $17.3 million of cash and cash equivalents compared to $6.2 million as of December 31, 2024. Cash as of December 31, 2025 excludes an additional $10.5 million received in February 2026 upon repayment of the unsecured promissory note issued by Companion Spine to Xtant in the divestiture transactions that closed in December 2025.2026 Financial GuidanceThe Company anticipates full-year 2026 revenue to be in the range of $95 million to $99 million. This outlook reflects anticipated organic growth in its core higher-margin biologics business, offset bythe impact of the Company's December 2025 sale of non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine, as well as the cessation of license revenue related to the Q-Code and amniotic membrane agreements that the Company received in 2025.Conference CallXtant Medical will host a webcast and conference call to discuss its fourth quarter and full-year 2025 financial and operating results at 8:30 am ET today, March 31, 2026.To access the webcast: https://www.webcaster5.com/Webcast/Page/3039/53616To access the conference call, dial 888-506-0062 (US) or 973-528-0011 (International) and reference Participant Access Code 581090.A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com for a period of one year.About Xtant Medical Holdings, Inc.Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.Non-GAAP Financial MeasuresTo supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's full year 2026 revenue guidance, anticipated organic growth in its core higher-margin biologics business, need for no further capital to fund its operations and expectation to be free cash flow positive in 2026. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results, financial performance and need for additional capital; the success of the Company's expanded field sales force to improve the Company's reach and leverage its outstanding contract portfolio and independent agent network; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; its ability to license intellectual property on commercially reasonable terms and to maintain any such licenses and its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission (SEC) on March 30, 2026. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.-- Tables Follow –XTANT MEDICAL HOLDINGS, INC.
Consolidated Balance Sheets
(In thousands, except number of shares and par value)

As ofDecember 31, 2025

As ofDecember 31, 2024
ASSETS

Current Assets:

Cash and cash-equivalents
$17,053

$6,199
Restricted cash

275

22
Trade accounts receivable, net of allowance for credit losses of $2,165 and
$1,437, respectively

17,803

20,660
Inventories

30,263

38,634
Note receivable

10,462

—
Prepaid and other current assets

2,389

1,601
Total current assets

78,245

67,116
Property and equipment, net

6,202

10,131
Right of use asset, net

3,192

829
Goodwill

6,074

7,302
Intangible assets, net

299

8,356
Other assets

133

103
Total Assets
$94,145

$93,837

LIABILITIES & STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable
$3,844

$7,918
Accrued liabilities

10,626

7,771
Current portion of long-term debt

3,500

—
Current portion of lease liability

622

703
Current portion of finance lease obligations

35

69
Line of credit

10,857

12,120
Total current liabilities

29,484

28,581
Long-term Liabilities:

Lease liability, net

2,665

166
Financing lease obligations, net

12

47
Long-term debt, plus premium and less issuance costs

11,026

22,038
Deferred tax liability

5

42
Total Liabilities

43,192

50,874

Commitments and Contingencies (Note 12)

—

—

Stockholders' Equity:

Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no
shares issued and outstanding

—

—
Common stock, $0.000001 par value; 300,000,000 shares authorized;
140,039,557 shares issued and outstanding as of December 31, 2025;
139,045,664 shares issued and outstanding as of December 31, 2024

—

—
Additional paid-in capital

305,439

302,738
Accumulated other comprehensive income

—

(316)
Accumulated deficit

(254,486)

(259,459)
Total Stockholders' Equity

50,953

42,963
Total Liabilities & Stockholders' Equity
$94,145

$93,837
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)

Three Months Ended
December 31,

Twelve Months Ended
December 31,

2025

2024

2025

2024
Revenue

Product revenue
$27,712

$30,011

$115,204

$115,765
License revenue

4,645

1,502

18,723

1,502
Total Revenue

32,357

31,513

133,927

117,267

Cost of Sales

14,603

15,489

49,654

49,051
Gross Profit

17,754

16,024

84,273

68,216

Operating Expenses

General and administrative

7,293

5,700

29,375

28,691
Sales and marketing

10,946

11,684

45,512

49,214
Research and development

459

522

2,102

2,385
Total Operating Expenses

18,698

17,906

76,989

80,290

Income (Loss) from Operations

(944)

(1,882)

7,284

(12,074)

Other Income (Expense)

Interest expense

(718)

(1,134)

(3,671)

(4,160)
Interest income

94

—

94

—
Unrealized foreign currency translation (loss)
gain

(206)

(101)

(60)

5
Gain on divestiture

3,281

—

3,281

—
Other income (expense)

91

(27)

73

(33)
Total Other Income (Expense)

2,542

(1,262)

(283)

(4,188)

Net Income (Loss) from Operations Before
Provision for Income Taxes

1,598

(3,144)

7,001

(16,262)

Provision for Income Taxes Current and
Deferred

(1,541)

(21)

(2,028)

(187)

Net Income (Loss)
$57

$(3,165)

$4,973

$(16,449)

Net Income (Loss) Per Share:

Basic
$0.00

$(0.02)

$0.04

$(0.12)
Dilutive
$0.00

$(0.02)

$0.03

$(0.12)

Shares used in the computation:

Basic

139,826,783

138,977,615

139,531,791

133,665,075
Dilutive

150,462,888

138,977,615

150,042,556

133,665,075
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Year Ended December 31,

2025

2024
Operating activities:

Net income (loss)
$4,973

$(16,449)
Adjustments to reconcile net income (loss) to net cash provided by (used in)
operating activities:

Depreciation and amortization

5,223

4,224
Non-cash interest

537

522
Loss (gain) on sale of fixed assets

251

(264)
Stock-based compensation

2,892

4,117
Provision for reserve on accounts receivable

1,404

823
Provision for excess and obsolete inventory

3,669

485
Gain on sale to Companion

(3,281)

—
Other

(76)

(5)

Changes in operating assets and liabilities, net of the effects of acquisitions:

Trade accounts receivable

(591)

(755)
Inventories

(1,999)

(2,494)
Prepaid and other assets

(1,537)

(218)
Accounts payable

(3,117)

1,033
Accrued liabilities

4,198

(2,915)
Net cash provided by (used in) operating activities

12,546

(11,896)

Investing activities:

Purchases of property and equipment

(2,382)

(4,113)
Proceeds from sale of fixed assets

232

383
Proceeds from sale to Companion, net of promissory note

10,049

—
Net cash provided by (used in) investing activities

7,899

(3,730)

Financing activities:

Borrowings on line of credit

100,066

112,640
Repayments on line of credit

(101,329)

(105,142)
Payments on long-term debt

(8,000)

—
Payments on financing leases

(67)

(65)
Proceeds from private placement, net of issuance costs

(65)

4,456
Proceeds from issuance of long-term debt

—

5,000
Debt issuance costs

(49)

(651)
Payment of taxes from withholding of common stock upon vesting and
settlement of restricted stock units

(126)

(178)
Proceeds from exercise of stock-based compensation

—

13
Net cash (used in) provided by financing activities

(9,570)

16,073

Effect of exchange rate changes on cash and cash equivalents and restricted cash

232

(149)

Net change in cash and cash equivalents and restricted cash

11,107

298
Cash and cash equivalents and restricted cash at beginning of year

6,221

5,923
Cash and cash equivalents and restricted cash at end of year
$17,328

$6,221
Reconciliation of cash and cash equivalents and restricted cash reported in the
consolidated balance sheets

Cash and cash equivalents
$17,053

$6,199
Restricted cash

275

22
Total cash and cash equivalents and restricted cash reported in the consolidated
balance sheets
$17,328

$6,221
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(in thousands)

Three Months Ended December 31,

Year Ended December 31,

2025

2024

2025

2024

Net Income (Loss)
$57

$(3,165)

$4,973

$(16,449)

Depreciation and amortization

1,819

1,148

5,223

4,224
Interest expense, net

624

1,134

3,577

4,160
Tax expense

1,541

21

2,028

187
Non-GAAP EBITDA

4,041

(862)

15,801

(7,878)

Net Income (Loss)/Total Revenue

0.2%

-10.0%

3.7%

-14.0%

Non-GAAP EBITDA/Total Revenue

12.5%

-2.7%

11.8%

-6.7%

NON-GAAP ADJUSTED EBITDA CALCULATION

Non-cash compensation

727

840

2,892

4,117
Gain on divestiture

(3,281)

—

(3,281)

—
Divestiture/acquisition-related expenses

122

—

491

338
Acquisition-related fair value adjustments

47

167

358

415
Unrealized foreign currency translation loss (gain)

206

101

60

(5)
Separation related expenses

—

192

23

682

Non-GAAP Adjusted EBITDA
$1,862

$438

$16,344

$(2,331)

Non-GAAP Adjusted EBITDA/Total Revenue

5.8%

1.4%

12.2%

-2.0%

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-reports-fourth-quarter-and-full-year-2025-financial-results-302729503.htmlSOURCE Xtant Medical Holdings, Inc.

Original: Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results